Treatment strategies for chronic myelomonocytic leukemia (CMML) are matched to risk. Lower-risk patients without symptoms are often monitored closely, people with low blood counts receive supportive care, those with higher-risk disease are treated with hypomethylating agents such as azacitidine or decitabine, and proliferative disease is often controlled with hydroxyurea. An allogeneic stem cell transplant remains the only treatment that can cure CMML, and it suits only fit patients.
This guide explains what CMML is, how doctors assess its risk, and how each treatment fits into a practical plan.
What Is Chronic Myelomonocytic Leukemia?
Chronic myelomonocytic leukemia is a hematologic cancer in which the bone marrow makes too many monocytes, a type of white blood cell. It sits at the crossroads of two disease families. Like the myelodysplastic syndromes (MDS), it causes ineffective, abnormal blood production, and like the myeloproliferative neoplasms (MPN), it can produce too many cells and an enlarged spleen.
Despite the similar names, CMML is a different disease from chronic myelogenous leukemia, which is driven by the BCR-ABL1 fusion gene, and from chronic lymphocytic leukemia, which involves lymphocytes. It is also distinct from acute myelomonocytic leukemia, a form of acute myeloid leukemia with many more immature blast cells.
Causes and risk factors
CMML arises from acquired mutations in blood stem cells. Genes commonly involved include TET2, SRSF2 and ASXL1, which regulate DNA methylation, RNA splicing and gene switching, while mutations in signaling genes such as RAS tend to drive proliferation. Age is the strongest risk factor, and most people are diagnosed after 60. Previous chemotherapy or radiation can also raise risk.
How CMML Is Diagnosed and Classified
Many patients have fatigue, weight loss, night sweats, infections, easy bruising or a full feeling under the left ribs from an enlarged spleen. Some have no symptoms, and the diagnosis follows a routine blood test showing a raised monocyte count.
Diagnosis requires a persistent monocytosis in the blood, with monocytes making up at least 10% of white cells, plus a bone marrow biopsy showing dysplasia or a clonal abnormality. Doctors must exclude other causes of high monocytes, such as infection or inflammation, and exclude CML and other myeloid cancers with genetic tests.
| Feature | Category | Why it matters |
|---|---|---|
| White cell count below 13 x 10⁹/L | Myelodysplastic CMML | Problems mainly from low counts; supportive care is central |
| White cell count 13 x 10⁹/L or higher | Myeloproliferative CMML | Spleen enlargement and symptoms; cytoreduction often needed |
| Blasts under 5% in blood and under 10% in marrow | CMML-1 (lower blast) | Generally more favorable |
| Blasts 5 to 19% in blood or 10 to 19% in marrow | CMML-2 (higher blast) | Higher risk of progression to acute leukemia |
Hematologists combine these features with blood counts, transfusion needs, chromosome results and mutations in prognostic scoring systems such as the CMML-specific prognostic scoring system (CPSS) and its molecular version. The score, together with the patient’s fitness, drives most treatment decisions.
Treatment Strategies for Lower-Risk CMML
Watchful waiting
If blood counts are acceptable and there are no symptoms, active treatment may not help. Regular blood tests and clinic visits allow early action if the disease changes. For many older patients, this is the right starting point.
Supportive care
Supportive treatment aims to relieve cytopenias (low blood counts):
- Red cell transfusions for symptomatic anemia, with iron chelation considered if many transfusions are needed
- Erythropoiesis-stimulating agents (such as epoetin) in selected patients with anemia and low transfusion needs
- Platelet transfusions for bleeding or very low platelets
- Prompt antibiotics for infections, as low neutrophils increase risk
Treatment Strategies for Higher-Risk or Symptomatic CMML
Hypomethylating agents
Chronic myelomonocytic leukemia that is higher risk, or that causes troublesome cytopenias, is usually treated with azacitidine or decitabine. These drugs reverse abnormal DNA methylation and can improve blood counts, reduce transfusion needs and slow progression in some patients. They are given in repeated cycles, by injection or infusion (an oral decitabine combination is also available in some countries). Several cycles are needed before the response can be judged.
Hydroxyurea for proliferative disease
For patients with a very high white count, large spleen or symptoms such as night sweats, oral hydroxyurea lowers cell counts and eases symptoms. It controls the disease but does not change its natural course.
Allogeneic stem cell transplant
Allogeneic hematopoietic stem cell transplantation replaces the diseased marrow with donor stem cells and offers the only chance of cure. It carries serious risks, including infection, graft-versus-host disease and treatment-related death, so it is reserved for fitter patients with higher-risk disease. Hypomethylating agents are sometimes given first to control the disease while a donor is found.
Clinical trials
Because standard options are limited, joining a clinical trial is a reasonable choice at any stage. Researchers are testing drugs aimed at specific pathways and mutations. Broader context on leukemia treatment from diagnosis onward can help you frame questions for your team.
Comparing the Main CMML Treatments
| Strategy | Typical patient | Main goal |
|---|---|---|
| Observation | Lower risk, no symptoms | Avoid unnecessary treatment |
| Supportive care | Anemia or low platelets | Relieve symptoms, prevent complications |
| Hypomethylating agents | Higher risk or significant cytopenias | Improve counts, delay progression |
| Hydroxyurea | Proliferative disease, large spleen | Control counts and symptoms |
| Stem cell transplant | Fit, higher-risk patients | Potential cure |
In my practice, the conversation always covers what matters most to the patient: living longer, feeling better, avoiding hospital visits, or all three. Those priorities shape whether we pursue intensive therapy or a gentler approach.
When to See a Doctor
If you have CMML, contact your care team promptly for:
- Fever or signs of infection
- New bruising, nosebleeds or bleeding gums
- Worsening breathlessness or tiredness
- Increasing fullness or pain under the left ribs
- Drenching night sweats or unexplained weight loss
These can signal low counts, an enlarging spleen, or progression toward acute leukemia, which needs prompt reassessment.
Frequently Asked Questions
Is CMML curable?
An allogeneic stem cell transplant is the only treatment that can cure CMML. Other therapies aim to control the disease, improve blood counts and quality of life. Many patients are not candidates for transplant because of age or other health conditions.
Does everyone with CMML need treatment right away?
No. People with lower-risk disease and no symptoms are often monitored without active treatment. Treatment begins when counts fall, symptoms appear or the disease shows signs of progression.
Can CMML turn into acute leukemia?
Yes, CMML can progress to acute myeloid leukemia, especially in higher-blast and higher-risk cases. Regular monitoring aims to catch this change early. Rising blasts, falling counts or new symptoms prompt a repeat marrow test.
How long do hypomethylating agents take to work?
Responses usually take several treatment cycles to appear, so doctors typically assess benefit after a few months. If the disease responds, treatment often continues as long as it remains effective and tolerated. More detail on leukemia treatments can help explain how cycles are scheduled.
Key Takeaways
- CMML combines features of MDS and MPN and mainly affects older adults.
- Treatment is guided by risk score, blood counts, symptoms and fitness.
- Supportive care, hypomethylating agents and hydroxyurea are the main non-curative options.
- Allogeneic stem cell transplant is the only potential cure.
